NEW DELHI: Biocon Ltd has secured marketing authorisation from the European Commission (EC) for Pebrilzo, its biosimilar version of pertuzumab, expanding its oncology portfolio and adding another regulatory milestone in the global breast cancer treatment market.
The approval covers the treatment of HER2-positive breast cancer across multiple stages of the disease in the European Union (EU). According to the company, Pebrilzo is the first biosimilar to receive European Commission marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach.
The development follows a positive recommendation from the EMA's Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026. It also comes shortly after the US Food and Drug Administration (USFDA) approved the drug on November 16, marking another significant step in Biocon's efforts to expand its presence in the global oncology market.
Pebrilzo contains pertuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), a protein that can promote the growth of certain breast cancer cells.
The biosimilar has been approved as a 420 mg concentrate for solution for infusion. It is indicated for use alongside trastuzumab and chemotherapy in the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory or early-stage breast cancer who are at high risk of recurrence.
It is also approved for adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
For metastatic or locally recurrent unresectable HER2-positive breast cancer, Pebrilzo is indicated in combination with trastuzumab and docetaxel for patients who have not previously received anti-HER2 therapy or chemotherapy for their metastatic disease.
The biosimilar is designed to provide an alternative to Roche's reference biologic Perjeta, which contains pertuzumab.
One of the notable aspects of the approval is the regulatory pathway through which Pebrilzo received authorisation.
The EMA's tailored clinical approach allows biosimilar developers to establish comparability through robust analytical characterisation and pharmacokinetic data, potentially reducing the need for routine comparative efficacy studies where scientifically justified.
Biocon said extensive structural and functional analytical characterisation, together with comparative clinical pharmacokinetic data, demonstrated that its pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety or efficacy.
The development highlights the evolving regulatory framework for biosimilars in Europe, where greater emphasis is being placed on analytical evidence and scientific justification in establishing biosimilarity.
Commenting on the development, Shreehas Tambe, CEO and Managing Director of Biocon Ltd, said the European Commission's approval marked a significant regulatory milestone for the company.
He added that pertuzumab had become Biocon's fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio and supporting its commitment to expanding access to affordable biologic therapies for patients with HER2-positive breast cancer.
The approval builds on Biocon's existing oncology biosimilar portfolio, which includes treatments such as trastuzumab and bevacizumab.
The regulatory approval also brings Biocon closer to commercialising Pebrilzo in Europe.
Under a global patent settlement and licensing agreement with Genentech, announced in October 2026, Biocon secured the earliest licensed launch date for Pebrilzo in the European Union and the United Kingdom in the first quarter of calendar year 2027.
The agreement also provides for a US launch in the third quarter of 2028, subject to applicable conditions.
The USFDA approval and European Commission authorisation strengthen Biocon's position in the competitive biosimilars market, particularly in oncology, where biologic therapies play an important role in treating complex cancers.
While the latest approval expands the potential availability of another pertuzumab biosimilar in Europe, its eventual impact on treatment access and healthcare costs will depend on commercial launch timelines, pricing and market adoption.
For Biocon, Pebrilzo represents an important addition to its oncology business as the company continues to expand its global biosimilar footprint.
